可孚醫療(301087.SZ):子公司以3769萬元競得湘陰縣一宗地塊使用權
格隆匯11月2日丨可孚醫療(301087.SZ)公佈,近日,公司全資子公司湖南可孚醫療設備有限公司(“可孚設備”)根據《湘陰縣自然資源局國有建設用地使用權網上掛牌出讓公吿》(湘陰自然資吿【2021】49號)要求,參與湘陰網掛(2021)49號地塊國有建設用地使用權競拍,以人民幣3769.00萬元競得該土地使用權,並於2021年11月2日取得《岳陽市公共資源進場交易確認書》(嶽公資證【2021】第295號)。
宗地位置:湘陰縣金龍新區金鳳大道西側、燎原路北側;土地面積:83291.55 平方米。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.